Cell and gene therapies fueled a reorganization within the US Food and Drug Administration’s Center for Biologics Evaluation and Research, as staff prepare for an influx of applications.
CBER’s Office of Tissues and Advanced Therapies now has another branch to handle gene therapies (Gene Therapies Branch II), as...






